文献速递造血干细胞移植与细胞治疗

StemRegenin-1扩增脐带血CD34+细胞生成祖T细胞并发挥功能

Generation and function of progenitor T cells from StemRegenin-1-expanded CD34+ human hematopoietic progenitor cells.
PubMed 文献 · Blood Adv · 2019-01-01

本研究探讨StemRegenin-1(SR1)扩增的脐带血CD34+造血干/祖细胞能否在体外大量生成祖T(proT)细胞,并在体内比较其胸腺定植与外周T细胞功能。结果显示SR1扩增使CD34+细胞扩增>250倍,可生成大量proT细胞;SR1 proT细胞体内胸腺定植与外周T细胞功能与未扩增naive proT细胞相当。

要点

  • SR1扩增脐带血CD34+细胞可达>250倍,支持大量生成proT细胞
  • SR1 proT细胞体内胸腺定植与外周T细胞功能与naive proT细胞相当
  • SR1扩增联合proT细胞生成有望减轻HSCT后T细胞免疫缺陷

核心结论

  • SR1扩增的脐带血CD34+细胞可在体外高效生成proT细胞,且SR1 proT细胞在体内保持胸腺定植与外周T细胞功能。

研究设计与样本

  • 体外扩增与分化实验,结合小鼠体内过继转移与竞争性转移,并用单细胞RNA测序分析外周CD3+ T细胞。

主要发现

  • SR1扩增脐带血可诱导CD34+ HSPC扩增>250倍,并可在体外分化生成大量proT细胞。
  • 与未扩增naive proT细胞相比,SR1 proT细胞表型改变,但体内胸腺定植与外周T细胞功能有效。
  • 竞争性转移中naive与SR1 proT细胞胸腺定植能力相当。
  • 单细胞RNA测序显示外周CD3+ T细胞含功能性T细胞亚群,T细胞受体库为多克隆。

临床怎么用

  • 支持将SR1扩增脐带血移植物与proT细胞生成联合用于减轻HSCT后T细胞免疫缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Broader clinical application of umbilical cord blood (UCB), as a source of hematopoietic stem/progenitor cells (HSPCs), is limited by low CD34+ and T-cell numbers, contributing to slow lymphohematopoietic recovery, infection, and relapse. Studies have evaluated the safety, feasibility, and expedited neutrophil recovery associated with the transplantation of CD34+ HSPCs from ex vivo expansion cultures using the aryl hydrocarbon receptor antagonist StemRegenin-1 (SR1). In a phase 1/2 study of 17 patients who received combined SR1-expanded and unexpanded UCB units, a considerable advantage for enhancing T-cell chimerism was not observed. We previously showed that progenitor T (proT) cells generated in vitro from HSPCs accelerated T-cell reconstitution and restored immunity after hematopoietic stem cell transplantation (HSCT). To expedite immune recovery, we hypothesized that SR1-expanded HSPCs together with proT cells could overcome the known T-cell immune deficiency that occurs post-HSCT. Here, we show that SR1-expanded UCB can induce >250-fold expansion of CD34+ HSPCs, which can generate large numbers of proT cells upon in vitro differentiation. When compared with nonexpanded naive proT cells, SR1 proT cells also showed effective thymus-seeding and peripheral T-cell functional capabilities in vivo despite having an altered phenotype. In a competitive transfer approach, both naive and SR1 proT cells showed comparable thymus-engrafting capacities. Single-cell RNA sequencing of peripheral CD3+ T cells from mice injected with either naive or SR1 proT cells revealed functional subsets of T cells with polyclonal T-cell receptor repertoires. Our findings support the use of SR1-expanded UCB grafts combined with proT-cell generation for decreasing T-cell immunodeficiency post-HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Singh J, Chen ELY, Xing Y, et al. Generation and function of progenitor T cells from StemRegenin-1-expanded CD34+ human hematopoietic progenitor cells. Blood Adv. 2019. PMID: 31648315. doi:10.1182/bloodadvances.2018026575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。